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Purpose:  The aim of this study is to report a case of oral bisphosphonate-related osteonecrosis of the jaw (BRONJ) resulting 
in implant failure. 
Methods:  A patient suspected of having BRONJ was referred to the Department of Periodontology, Kyung Hee University 
School of Dentistry for the evaluation and treatment of exposed bone around implants. 
Results:  The patient, who had been taking oral bisphosphonates (BPs) for about a year, was successfully treated with systemic 
antibiotics, chlorhexidine mouth rinse, explantation, and surgical debridement of necrotic bone.  
Conclusions:  The results of this case suggest that a patient taking BPs orally should be treated cautiously. Appropriate man-
agement including cessation of BPs and respective dental treatment may reduce the development of BRONJ.
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Case Report
INTRODUCTION
Bisphosphonates (BPs) are drugs for inhibiting bone re-
sorption, widely used for the treatment of osteoporosis, mul-
tiple myeloma and skeletal complications of bone metasta-
ses. BPs were proven to inhibit decreases in bone density and 
prevent bone fracture by reducing activation of osteoclasts 
and inducing apoptosis of osteoclasts. The two main catego-
ries of BPs are the non-nitrogen and nitrogen-containing 
BPs [1,2]. Alendronate is an oral nitrogen-containing BP and 
the most commonly used drug to treat osteoporosis and os-
teopenia. Even though BPs have clinical efficacy, a number 
of cases of osteonecrosis of the jaw involving a patient treat-
ed with BPs for a long period of time have been reported 
worldwide since Marx [3] reported the first case, and this has 
been recognized as a serious adverse effect of these drugs. 
The American Association of Oral and Maxillofacial Sur-
geons (AAOMS) suggests patients may be considered to have 
bisphosphonate-related osteonecrosis of the jaw (BRONJ) if 
each of the following 3 characteristics are present: 1) current 
or previous treatment with BPs, 2) exposed, necrotic bone in 
the maxillofacial region that has persisted for more than 8 
weeks, and 3) no history of radiation therapy to the jaws [4]. 
The American Dental Association Council on Scientific Af-
fairs (ADA CSA) reported that the incidence of BRONJ for 
patients receiving alendronate for a long period of time was 
estimated to be 0.7 per 100,000 person years of exposure [5]. 
Even though BRONJ occurs infrequently, risk factors such as 
systemic/local factors, potency of BPs and period of taking 
BPs may raise the incidence rate of BRONJ [6]. Recently, im-
plant treatment cases have increased markedly. Furthermore, 
as the population ages, the numbers of patients who have 
been treated with BPs or continue to use them for treatment 
of osteoporosis is on the rise. As a result, the risk of BRONJ 
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for patients who are receiving BPs is increasing after implant 
placement.
This case report illustrates a 67-year-old female patient who 
had received oral BPs and developed a significant bone de-
fect with necrosis after proper implant placement, and was 
treated with explantation. 
CASE DESCRIPTION
Case report protocol (KHD IRB 2010-1) was approved by the 
Institutional Review Board of Kyung Hee University Dental 
Hospital. A 67-year-old female was referred to the Depart-
ment of Periodontology, Kyung Hee University School of 
Dentistry with chief complaints of pain on chewing and gin-
gival swelling in the upper right molar area beginning 2 
months previously. She was treated with non-surgical peri-
odontal therapy and antibiotic administration for 1 month at 
a private clinic. Two dental implants had been placed with a 
ridge split in the upper right second premolar and the first 
molar areas at the private clinic 1 year earlier. The patient had 
taken medicine for hypertension and rheumatoid arthritis. 
She had been diagnosed with osteoporosis, and thus had a 
1-year history of taking oral BPs, 70 mg alendronate (Fosamax, 
Merck, Whitehouse Station, USA) once per week. She had 
been taken off alendronate 5 months before her arrival at the 
Kyung Hee University School of Dentistry, because a bone 
density test and a Vitamin D test at the Department of Endo-
crinology showed a normal range. However, her serum C-
terminal cross-linked telopeptide of type I collagen (CTX) 
level was low, measured at 21 pg/mL. On the first day of den-
tal examination, she complained of pain on palpation, and 
gingival swelling and redness on the buccal side of the two 
implants. Exposure of the necrotic bone was observed be-
tween the upper right first premolar tooth and second pre-
molar implant. However, we could not determine how long 
it had been exposed because the patient was reffered to us 
for treatment. The upper right second premolar implant 
showed 3 degrees of mobility, pain on percussion, and a 10-
mm probing depth in the buccal and distal areas. Alveolar 
bone resorption with internal scattered residual bony frag-
ments was seen between the two implants on a panoramic 
radiograph (Fig. 1) and computed tomography (Fig. 2). Wid-
ening of the periodontal ligament space and a radiolucent 
lesion in the apical area of the upper right first premolar 
were also seen.
During the first visit, inflammatory tissue around the im-
plants was removed following flap reflection under local an-
esthesia, and the flap was sutured. Gingival swelling de-
creased after 1 week, but there was no change in exposure of 
the necrotic bone (Fig. 3). Explantation and extraction of the 
upper right first premolar was planned to prevent additional 
bone destruction. After an intrasulcular incision was made 
around the implants and the tooth to be extracted under lo-
cal anesthesia, a vertical incision was done at the mesiobuc-
cal line angle of the upper right canine. The full thickness 
flap was then elevated, and exposure of the implant threads 
was noticed on the buccal and inter-implant area (Fig. 4).
After extraction of the upper right first premolar, perfora-
tion on the buccal side of the extraction socket was seen and 
the extraction socket was also penetrated to the upper right 
second premolar implant distally at the apical area (Fig. 5). 
The two implants were removed with dental forceps and an 
elevator. The remaining granulated tissue was removed and 
a generalized ostectomy was done. The sharp edges of ne-
crotic bone were trimmed by a high speed drill to prevent 
inflammation of the soft tissue and to manage pain. The re-
Figure 1. Pre-operative panoramic radiograph. Figure 2. Bone resorption is prominent between #15i and #16i with 
internal scattered residual bony fragments. Journal of Periodontal
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maining necrotic bone was partially (not entirely) removed 
by the high speed drill. Interestingly, during this procedure, 
distinct bone surface bleeding was not seen to any great ex-
tent (Fig. 6).
Tetracycline (50 mg/mL) irrigation was performed, and the 
flap was extended coronally to effect primary closure and 
was then sutured (Fig. 7). Amoxicillin 500 mg (Amoxapen
®, 
Chong Kun Dang Pharmaceutical Co., Seoul, Korea) and Ibu-
profen 200 mg (Brufen
®, Sam-il Co., Seoul, Korea) were each 
administered for 1 week, and a mouth rinse with 0.12% chlo-
rhexidine was recommended for the following 2 weeks. The 
following day, the patient complained of a slight fever, but it 
was relieved 2 days later. Stitch-out was done after 1 week 
(Fig. 8) and wound dehiscence was seen on the extraction 
socket of the upper right first premolar. The patient was in-
structed to keep using chlorhexidine as a mouth rinse. After 4 
weeks, pin-point bone exposure was detected on the distal 
side of the upper right canine, but the patient did not have 
any discomfort or pain. After 4 months, no additional bone 
exposure was found at the operation site (Fig. 9), and there 
were no significant findings on the panoramic radiograph 
(Fig. 10). The patient is wearing a removable partial denture 
at the moment and receives follow-up care on a regular basis.
DISCUSSION
The patient in this case had a history of taking BPs for 1 
year and no history of radiation therapy to the jaws, but there 
was no way to ascertain how long the necrotic bone had 
been exposed in the oral cavity because she was referred 
without any further information. However, we estimated 
that this patient met the three requirements of BRONJ as 
Figure 5. After extraction of #14, fenestration is observed on the 
buccal area.
Figure 6. Explantation & removal of necrotic bone was performed. 
Figure 3. Necrotic bone is exposed between #14 and #15i. 
Figure 4. Fixture threads are exposed on the buccal and interproxi-
mal area. Journal of Periodontal
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suggested by AAOMS [4] and thus was diagnosed with 
BRONJ. 
Although there has not been sufficient research to deter-
mine the nature of BRONJ, some risk factors have been con-
nected with an increasing tendency toward the incidence of 
BRONJ for patients taking BPs. Although few reports have 
investigated risk factors, it has been suggested that risk fac-
tors such as potency of BPs, period of taking BPs, and sys-
temic/local factors could influence the incidence of BRONJ 
[6]. The more powerful potency of BPs and the longer period 
of taking BPs, the greater the occurrence of BRONJ. Local 
risk factors which increase the incidence of BRONJ are as 
follows: extraction, implant placement, surgical procedures 
including osteotomy, and anatomic structures such as tori. 
Systemic risk factors include old age, diabetes mellitus, use 
of steroids, cancer therapy, and smoking. The most common 
risk factors in dentistry are intraoral surgery such as extrac-
tion and implant placement. It was reported that the inci-
dence rate of BRONJ in patients taking BPs who had in-
traoral surgery was seven times higher than that of those 
who did not have surgery [7]. In this case, the patient took 
alendronate for only 1 year. However, we assumed that old 
age (67-year-old patient), extraction and implant placement 
worked as negative risk factors for BRONJ.
BPs were divided into two types depending on administra-
tion method - intravenous infusion and oral administration. 
Patients taking oral BPs manifested less bone exposure and 
mild symptoms compared to patients with IV BPs [8]. It has 
been reported that oral BPs had a lower risk since it took lon-
ger to develop bisphosphonate-induced osteonecrosis be-
cause of a slower accumulation rate in the bone [2]. However, 
there are many patients taking oral BPs for the treatment of 
osteoporosis, so it is very important to assess risks, especially 
when patients took BPs for a long period of time (longer than 
3 years). Marx et al. [9] suggested using serum levels of morn-
ing fasting CTX to assess patients’ risks of developing BRONJ 
Figure 9. Post-operative view (4 months later).
Figure 10. Post-operative panoramic radiograph.
Figure 7. Suture.
Figure 8. Post-operative view (1 week later).Journal of Periodontal
& Implant Science JPIS
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by oral administration of BPs. CTX shows the healing poten-
tial of bone as a marker of bone turnover [10]. This telopep-
tide fragment is cleaved from the main crosslink chains of 
collagen by the osteoclast during bone resorption. Therefore, 
its serum level is proportional to the osteoclastic activity. The 
CTX value can be used as a marker for deciding the optimal 
timing of surgical intervention. Marx et al. [9] assessed 30 
cases of BRONJ, and based on 17 out of 30 patients who were 
still receiving BPs at the beginning of the study, they classi-
fied risks of developing BRONJ into 3 classes depending on 
the CTX value. In this population, CTX values less than 100 
pg/mL were classified into a high risk group, values from 100 
to 150 pg/mL into a moderate risk group, and values higher 
than 150 pg/mL into a minimal risk group. The authors sug-
gested that clinicians might consider implementing a “drug 
holiday” to achieve the desired (low risk) CTX level before 
initiating oral surgical procedures. The CTX value was 21 pg/
mL in this case, which means the patient was in the high risk 
group. She had a history of delaying intraoral minor surgery 
for 1 to 2 months in the Department of Oral and Maxillofa-
cial Surgery, Kyung Hee University School of Dentistry after 
being referred to the Department of Endocrine Medicine.
One of the most common clinical features associated with 
BRONJ is an exposure of necrotic bone. In the early stages, 
radiographic changes are not noticed, and patients do not 
have symptoms. However, patients may have severe pain if 
secondary infection or trauma on soft tissue above the sharp 
edges of the exposed bone occurred [11]. In this case, the pa-
tient complained of pain on chewing and gingival swelling 
on the upper right 2 implants which were placed 1 year earli-
er, and necrotic bone was observed around the implants. The 
patient was diagnosed as possessing stage 2 of BRONJ by the 
criteria of AAMOS [4], and stage 2 treatment strategy was 
carried out - selective removal of necrotic bone. Only the 
sharp necrotic bone which triggered soft tissue inflamma-
tion and pain was removed. Antibiotics and analgesics were 
administered for the control of pain and mouth rinse with 
0.12% chlorhexidine was recommended. Pinpoint bone ex-
posure was observed at the surgical site, but it was covered by 
soft tissue in 6 weeks, and healing was satisfactory. The treat-
ment objectives for patients with an established diagnosis of 
BRONJ are to alleviate pain, eliminate inflammation in soft 
and hard tissue, and minimize the progression of bone ne-
crosis [6]. Surgical debridement is an effective treatment for 
necrotic bone [12,13]. Removal of necrotic bone which con-
stantly irritates soft tissue and recontouring of the bony 
shape are needed [14]. However, it is difficult to expose viable 
bleeding bone for the surgical margin since BPs affect the 
entire jaw bone and the necrotic bone margin is indefinite. 
Therefore, custom osteotomy is impossible, and it is recom-
mended that loose segments of bony sequestrum be re-
moved without exposing uninvolved bone [15]. Marx et al. [16] 
reported that attempts to accomplish debridement, cover the 
exposed bone with flaps, or bone-contouring procedures 
have mostly been counterproductive and have led to further 
exposed bone, worsening of symptoms, and a greater risk for 
a pathologic fracture of the jaw. Therefore, those procedures 
were to be limited only to cases where there was no response 
to nonsurgical management or continuation of symptoms. 
Since necrotic exposed bone itself is not painful, it is sug-
gested that it retained for the preservation of jaw structure 
and normal function. 
In terms of implant failure related to BPs, Jeffcoat [17] re-
ported a 100% success rate for 102 implants with no clinical 
evidence of infection, pain or bone necrosis in patients re-
ceiving oral BPs for a mean duration of 3 years. Madrid and 
Sanz [18] reviewed 1 prospective and 3 retrospective studies 
and reported that there was no BRONJ after implant place-
ment in 217 patients who took oral BPs for less than 5 years. 
They concluded that oral BP administration did not affect 
the short term success rate of an implant (1 to 4 years). Al-
though the implant failure rate due to BRONJ is low for pa-
tients administered oral BPs, implant failure is possible for 
patients who took BPs for only 1 year. Thus, it is suggested 
that if implant placement were planned, informed consent 
should be provided relating to possible future implant failure 
and osteonecrosis of the jaw for patients taking oral BPs. Dis-
continuation of oral BPs can be considered from 3 months 
prior to surgery to 3 months after surgery if the patient’s sys-
temic condition allows it, in cases where the administration 
period of BPs was greater than 3 years [4]. A number of stud-
ies have recently reported that the incidence of BRONJ de-
creased after discontinuation of oral BPs therapy [19,20]. 
As the aging population grows, the number of patients with 
osteoporosis increases, thus the number of patients taking 
BPs for the treatment of osteoporosis is also on the rise. 
Therefore, further consideration of the long term stability of 
BPs is needed. As we have discussed above, serum CTX could 
be used as a systemic marker for assessment for the risk of 
BRONJ; thus further studies about serum CTX are needed. 
In addition, more detailed studies should be conducted to 
decide if modification of a treatment plan for implant place-
ment and extraction (depending on the period of adminis-
tration) is necessary for patients taking oral BPs.
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